NeoPharm CO. LTD (092730) — Cash Flow-to-Debt Ratio
NeoPharm CO. LTD (092730) has a Cash Flow-to-Debt Ratio of 0.31x as of September 2025, meaning its operating cash flow of ₩5.88 Billion could theoretically repay 0% of its total liabilities (₩18.97 Billion) in one year. See 092730 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
NeoPharm CO. LTD Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for NeoPharm CO. LTD across 11 annual periods. Also explore NeoPharm CO. LTD (092730) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for NeoPharm CO. LTD (2012–2024)
Year-by-year debt coverage analysis for NeoPharm CO. LTD. For market capitalisation and broader financial context, see NeoPharm CO. LTD stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 1.20x | ₩18.63 Billion | ₩15.56 Billion | ▼ -10.2% |
| 2023 | 1.33x | ₩23.26 Billion | ₩17.43 Billion | ▼ -3.5% |
| 2022 | 1.38x | ₩18.16 Billion | ₩13.14 Billion | ▼ -16.5% |
| 2021 | 1.65x | ₩21.68 Billion | ₩13.10 Billion | ▲ +47.9% |
| 2020 | 1.12x | ₩17.07 Billion | ₩15.26 Billion | ▼ -0.8% |
| 2019 | 1.13x | ₩19.22 Billion | ₩17.05 Billion | ▼ -4.9% |
| 2018 | 1.19x | ₩16.18 Billion | ₩13.64 Billion | ▲ +1.5% |
| 2017 | 1.17x | ₩10.65 Billion | ₩9.11 Billion | ▲ +1.3% |
| 2016 | 1.15x | ₩9.16 Billion | ₩7.94 Billion | ▲ +47.4% |
| 2015 | 0.78x | ₩6.09 Billion | ₩7.79 Billion | ▲ +485.1% |
| 2012 | 0.13x | ₩564.34 Million | ₩4.22 Billion | — |